A pilot study of CS-1008, a humanized monoclonal antibody targeting death receptor 5, alone or in combination with imatinib mesylate or sunitinib
|Effective start/end date||9/25/07 → 12/31/10|
- DAIICHI SANKYO, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.